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Abstract
Background: Microseminoprotein-beta (MSMB) regulates apoptosis and using genome-wide association studies the
rs10993994 single nucleotide polymorphism in the MSMB promoter has been linked to an increased risk of developing
prostate cancer. The promoter location of the risk allele, and its ability to reduce promoter activity, suggested that the
rs10993994 risk allele could result in lowered MSMB in benign tissue leading to increased prostate cancer risk.
Methodology/Principal Findings: MSMB expression in benign and malignant prostate tissue was examined using
immunohistochemistry and compared with the rs10993994 genotype. Urinary MSMB concentrations were determined by
ELISA and correlated with urinary PSA, the presence or absence of cancer, rs10993994 genotype and age of onset. MSMB
levels in prostate tissue and urine were greatly reduced with tumourigenesis. Urinary MSMB was better than urinary PSA at
differentiating men with prostate cancer at all Gleason grades. The high risk allele was associated with heterogeneity of
MSMB staining and loss of MSMB in both tissue and urine in benign prostate.
Conclusions: These data show that some high risk alleles discovered using genome-wide association studies produce
phenotypic effects with potential clinical utility. We provide the first link between a low penetrance polymorphism for
prostate cancer and a potential test in human tissue and bodily fluids. There is potential to develop tissue and urinary MSMB
for a biomarker of prostate cancer risk, diagnosis and disease monitoring.
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Introduction
Microseminoprotein-beta (MSMB) is the second most abundant
protein found in semen after prostate-specific antigen (PSA) [1].
Unlike PSA, MSMB is not directly regulated by androgens and its
level is not affected by hormone manipulation [2,3,4]. Prostate
specificity of MSMB expression was initially demonstrated in
rodents [5,6] and supported by the development of a prostate
mouse model that used the msmb promoter/enhancer region to
target prostate specific expression [7,8]. However studies in
humans suggest MSMB can be expressed in a number of secretory
and mucosal tissues, albeit at much lower levels than in prostate
[9,10,11,12,13,14].
Two genome wide association studies (GWAS) have identified a
tag small nucleotide polymorphism (SNP), rs10993994, on 10q
that is strongly associated with an increased risk of developing
prostate cancer [15,16]. This SNP is in the 59 UTR of MSMB.
The risk allele is common, with a frequency of ,30–40% in
Europeans and 70–80% in men of African ancestry, and confers
an increased risk of prostate cancer of 1.3 (per allele odds ratio).
This association is observed in both Europeans and African-
Americans and appears to be independent of age of diagnosis and
tumour grade [17]. Fine scale mapping has not identified any
other independently associated variants in the region. Further-
more, a recent study in cell lines has shown that the risk allele (T)
significantly reduced the promoter activity of the gene to 13% of
that in the low risk allele (C) [18]. As this SNP lies within the
MSMB proximal promoter region reduced promoter activity is
suggested to occur via altered transcription factor binding sites
such as CREB [19]. These data strongly suggest that the
rs10993994 T allele is causally associated with prostate cancer
risk, and that this association may be mediated through reduced
expression of the MSMB protein in benign prostate tissue. It has
been reported that MSMB mRNA in cell lines was reduced in cells
homozygous for the risk allele, which suggests a hypothesis
whereby reduced MSMB expression in individuals with the
rs10993994 risk allele could lead to reduced regulation of cell
growth and an increased risk of tumourigenesis [19].
Several groups have studied MSMB expression in prostate
cancer and all have found higher levels of MSMB in benign and
normal tissue or serum when compared with material from
tumours [2,3,4,12,20,21,22,23]. To date no studies have been
completed in urine. High levels of MSMB in benign tissue is
consistent with the hypothesis that MSMB binds to cell surface
receptors and regulates prostate growth by controlling apoptosis
possibly via MAP kinase/AKT signalling [24,25,26].
Prostate cancer is the most common solid male cancer in the
UK. At present the best diagnostic tool is serum PSA while urinary
PCA3 mRNA is also used as a useful diagnostic test particularly for
men with raised PSA and an initial negative biopsy [27]. However,
the need for a digital rectal exam prior to testing precludes its use
as a screening tool. Urinary PSA has been reported as a potentially
useful diagnostic tool in men with serum PSA 2.5–10 ng/ml and is
of particular interest in screening and monitoring disease as it is
more acceptable to patients.[28].
We have used immunohistochemical studies of MSMB in benign
prostate tissue to demonstrate a relationship betweenMSMB protein
expression and the rs10993994 genotype. We have developed a
urinary ELISA assay to examine the association between urinary
PSA, MSMB levels and MSMB genotype to determine if this has
potential for clinically use as a screening or diagnostic tool.
Materials and Methods
Ethics Statement
Full ethical approval was obtained for all human sample
collections from either the West Midlands Multi-Centre Research
Ethics Committee or the Trent Multi-Centre Research Ethics
Committee. All samples were obtained with written consent and
analysed anonymously.
Patient cohorts
Tissue, blood and urine samples from patients with diagnosed
prostate cancer were obtained from Addenbrooke’s Hospital, Cam-
bridge, UK (radical prostatectomies collected between 2001 and
2008) and The Institute of Cancer Research (biopsy and trans-
urethral prostatectomies collected from 1995–2002). Normal/benign
patients were recruited as part of the IMPACT study, a study of
prostate cancer risk in men with BRCA1/2 germline mutations at The
Institute of Cancer Research (05/MRE07/25) [29]. This cohort had
no history of prostate disease and included men with mutated and
wild-type (control) BRCA1 and BRCA2. Median age, PSA and
Gleason scores of the cohorts used are given in Figure S1.
Not all patients had good quality tissue for IHC, DNA for
genotyping, serum PSA measurements and urine available. To
overcome this, patients were split into three cohorts to answer
specific questions. 168 patients with good quality tissue were used
for the IHC study depicted in Figure 1. Samples from 133 of the
patients were made into a tissue microarray (TMA) containing
multiple cores from normal/benign regions (.3), prostatic intra-
epithelial neoplasia (PIN) and at least two distinct regions of
tumour for each patient. The remaining cases were part of an
additional TMA of young onset prostate cancer patients (defined
as diagnosed at #60 years) from the UK Genetic Prostate Cancer
Study. This TMA included multiple normal/benign and tumour
regions for 35 patients. n = indicates the number of events rather
than the number of cores examined i.e. where heterogeneous
pathology was found both regions were scored independently.
Only 145 patients had DNA which could be used for
genotyping as shown in Figure 2B. Complete radical prostate
sections or very large tissue sections were available from 32
patients from the Addenbrookes cohort.
For the MSMB ELISA shown in Figure 3 89 men with prostate
cancer that had tissue, DNA and a urine sample were used. The
normal/benign patients were recruited as part of the IMPACT
study, a study of prostate cancer risk in men with BRCA1/2
germline mutations (n = 215). All urine samples were obtained
prior to any digital rectal exam, aliquoted and frozen immediately
at 280uC. Where available age, PSA and Gleason score at
diagnosis was determined for each patient.
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Figure 1. MSMB immunohistochemistry is specific for benign prostate glands. MSMB immunohistochemistry was performed on TMAs
using a BondMax autostainer. For all sections nuclei are shown in blue and MSMB staining in brown. (A) MSMB was not present in urothelium (left
panel), black arrow - urothelium, white arrow - prostate, seminal vesicle (central panel), black arrow - seminal vesicle, white arrow - prostate, bladder
(right panel), black arrow - fat cells, white arrow - bladder muscularis propria. (B) MSMB staining in the prostate is specific for benign glands (white
arrows) and not prostate tumour cells (Gleason 3) (black arrows). MSMB also failed to stain atrophic benign glands. Examples of the staining criteria
(none/weak, moderate and strong) applied to the immunohistochemistry. Results of the staining were highly significant as calculated using a Kruskal-
Wallis test. n represents the number of pathological events scored.
doi:10.1371/journal.pone.0013363.g001
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Genotyping
Genotyping was completed as previously described [15]. DNA
was extracted from whole blood for series 2 and 3, either
commercially by GeneProbe or with Qia-ampH DNA Mini Kit
(Qiagen) according to manufacturer’s instructions. Genotyping of
samples was performed by 59exonuclease assay (TaqmanTM) using
the ABI Prism 7900HT sequence detection system according to
the manufacturer’s instructions. Primers and probes were supplied
directly by Applied Biosystems as Assays-By-DesignTM.
Immunohistochemistry
All immunohistochemistry (IHC) was performed using a
Bondmax automated stainer and anti-MSMB antibody (Abcam)
(1:400) on tissue from series 1 and 2. For the multi-normal/tumour
array a 48 core TMA from Stretton Scientific was used. Nuclei
were counterstained with hematoxylin and slides imaged using an
Aperio scanning system. Pathology was confirmed by a specialist
uro-pathologist (AW) prior to the scoring of any immunohisto-
chemical staining. Scoring was performed by two observers, one of
whom was a uro-pathologist (AW), and a consensus obtained.
Sequential hematoxylin and eosin stained sections were used to
confirm pathology. Staining was graded as; ‘none’ - no staining,
‘weak’ - not all epithelial cells stained and pale staining, ‘moderate’
– most or all epithelial cells stained moderately, ‘strong’ - all
epithelial cells stained strongly (Figure 1B). Where sections
contained heterogeneous staining an overall consensus was
achieved based on the relative proportions of the different scores.
Where heterogeneous pathology existed within cores e.g. benign
and tumour regions side-by-side, each region was scored as a
separate event. n = indicates the number of events rather than the
number of cores examined.
PSA and MSMB measurements
Serum and urinary PSA (Free & Total) & creatinine assays were
performed by the NIHR Cambridge Biomedical Research Centre
Core Biochemistry Assay Laboratory, Addenbrookes Hospital
using the ProStratus Free/Total PSA DELFIA kit (Perkin Elmer
Life & Analytical Sciences) and Dimension RXL analyser
(Siemens Healthcare). For the MSMB ELISA all procedures were
performed with shaking at room temperature. Wells were washed
between each step three times with 0.05% PBS-Tween and a
BioTek Elx50 platewasher. Ninety-six well plates (Fisher Scientific)
were coated overnight at 4uC in mouse anti-PSP94 antibody
(1:1000, Abcam) diluted in PBS. Wells were blocked with 1% BSA
(Sigma) for 1 hour before 50 ml of sample or standard was added
to each well in duplicate and incubated for a further 2 hours.
Serial dilutions (2520.78 mg/ul) of recombinant PSP94 (rPSP94,
R&D Systems) were used as a control on each plate. Goat anti-
MSMB (R&D systems 0.2 mg/ml) was added to each well for
1 hour followed by a1 hour incubation with donkey anti-goat-
HRP (Abcam, 1:20,000). To visualize 100 ml TMB (Sigma) was
added to each well for 15 mins. The reaction was stopped by
acidifying with 50 ml HCl and absorbance measured at 450 nm
using a Lucy II spectrophotometer.
The dynamic range of the ELISA was determined to be 0.01–
100 mg/ml although the non-linear range was much greater. Any
Figure 2. The rs10993994 SNP correlates with MSMB protein expression in benign glands by immunohistochemistry. (A) An example
of mega-block staining of large prostate sections showing homogenous (left panel) or heterogeneous (right panel) staining. MSMB
immunohistochemistry was scored as before as strong, moderate, weak or lost for each patient and stratified according to genotype; T - high
risk, C- low risk. p-values were calculated using a Kruskal-Wallis test. n represents the number of pathological events scored.
doi:10.1371/journal.pone.0013363.g002
MSMB and rs10993994 Correlate
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plate exhibiting .20% variability in the standard curve was
deemed to have failed and repeated. Intra- and inter-assay
variability was 8.8% and 22% respectively. Effects on protein
stability were shown to be ,20% after testing by freeze thawing 3
times before assaying or incubating pre-diluted rPSP94 -3 for
4 hours at room temperature prior to assaying. Recovery from
different fluids was determined to be ,20% by diluting rPRDX-3
in either PBS, 0.1% bovine serum albumin (Sigma) or 10% goat
serum (Dako Cytomation). MSMB concentration was determined
by interpolation of values from non-linear regression of the
sigmoidal standard curve. The concentration of all urine samples
was normalised using creatinine measured using a creatinine assay
Figure 3. The rs10993994 SNP correlates with urinary MSMB protein expression. Urinary MSMB and PSA concentrations were determined
and normalised to creatinine. (A) Urinary MSMB was determined by ELISA for the normal/benign patient cohort and a smaller cohort with a prostate
cancer diagnosis. The same cohort was also tested for urinary PSA and serum PSA values collated. ROC curves were generated; AUC = area under the
curve, confidence intervals are given in brackets and p values are given at 95% confidence levels. The difference between urinary MSMB and PSA ROC
curves p = 0.0021. The difference between the urinary MSMB and The tumour cohort was further stratified by Gleason sum score (B). Urinary MSMB
and PSA from low Gleason samples (6 and 7) were compared to high Gleason (8 and 9) samples and ROC curves generated and displayed as before.
Urinary MSMB was also stratified according to the rs10993994 risk allele (C). n = the number of individuals examined in each group.
doi:10.1371/journal.pone.0013363.g003
MSMB and rs10993994 Correlate
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kit (R&D Systems) and the slope of standard curve determined by
known standards (20–0.3125 mg/dL) and linear regression. Only
samples which could be interpolated from the standard curves
without extrapolation were included in the analysis.
Statistical Methods
All statistics including linear regression and interpolation for the
ELISA assay were performed using GraphPad Prism 5. To
compare sensitivity and specificity of measurements in the tumour
cohort compared to the benign cohort receiver-operator curves
(ROC) were performed. A 1-way ANOVA test with a Kruskal-
Wallis correction was used to determine if tissue or urinary MSMB
levels were significantly different between the benign and tumour
cohorts when the tumour cohort was stratified according to
Gleason grade or genotype. A Mann Whitney two-tailed student
t-test was used for all pairwise comparisons. For all experiments a
p-value of 0.05 was considered significant.
Results
Other than in benign prostate no normal or tumourigenic
tissues demonstrated any MSMB staining suggesting that at the
protein level in tissue MSMB is highly prostate specific (Figure 1A
and Figure S2). In particular the tissues surrounding the prostate
e.g. urothelium, seminal vesicles and bladder muscularis propria
layer showed no staining whereas adjacent benign prostate glands
were heavily stained (Figure 1A).
Consistent with previous reports benign prostate glands showed
significantly higher levels of staining compared with tumourigenic
regions in our cohort (p,0.0001, Figure 1B and Figure S1)
[2,3,4,12,20,21,22,23]. MSMB staining was also consistently lost
in prostatic intra-epithelial neoplasia (PIN) compared to benign
tissue (p,0.0001) suggesting that it may be an early, causal, event
in tumourigenesis. Staining for MSMB in benign tissue ranged
from homogeneous, which was most commonly seen with strong
staining (Figure 2A, left panel) and variable, heterogeneous
staining frequently seen with weak and moderate staining
(Figure 2A, right panel).
MSMB staining in tissue was significantly associated with the
rs10993994 genotype (p,0.0001), staining being weakest in men
homozygous for the high risk allele (TT) and strongest in CC
homozygotes (Figure 2B). There was no evidence of an association
between MSMB staining and age or PSA at diagnosis in this
malignant series of men (Figure S3).
We determined urinary levels of MSMB in 215 normal/benign
men with no history of prostate disease and 89 men with prostate
cancer (Figure S4). Consistent with the association in prostate
tissue there was a significant decrease in urinary MSMB in men
with tumours compared with men with no history of prostate
disease (Supporting Document 4A) (p,0.0001). Urinary MSMB
significantly improved upon urinary PSA, but not serum PSA, for
prostate cancer diagnosis in this cohort (difference between urinary
MSMB and PSA ROC curves 0.21, 95% CI: 0.075, 0.34,
p = 0.0021) (Figure 3A). When the tumour samples were stratified
into low (6 and 7) and high (8 and 9) sum Gleason scores urinary
MSMB demonstrated high levels of specificity and sensitivity
particularly when compared to urinary PSA (Figure 3B). There
was a significant decrease in urinary MSMB with the high risk
allele compared (TT) to the low risk allele (CC) (Figure 3C)
(p = 0.0319) although this was not reflected in a significant
difference in ROC curves. Raised benign urinary MSMB is
unlikely to reflect an increased benign prostate volume as there
was no significant increase in urinary MSMB with age (Supporting
Document 4B) (p = 0.543). To demonstrate that the correlation
was specific for the rs10993994 genotype we compared urinary
MSMB levels and BRCA1 and BRCA2 germline mutation status,
which are known prostate cancer risk factors [30,31], and found
no link (Figure S4).
Discussion
This is the first study to describe the relationship between the
risk allele of the tag SNP rs10993994 and MSMB levels in benign
and tumour prostate tissue and to correlate the protein level with
genotype and aggressiveness of prostate cancer. The almost
complete loss of MSMB in PIN (Figure 1B) suggests that reduced
MSMB is an early event in tumourigenesis consistent with an
association between prostate cancer risk and the rs10993994
genotype.
There is strong evidence linking the rs10993994 SNP in the
MSMB promoter region to an increased risk of developing prostate
cancer [15,16]. MSMB has been studied by a large number of
groups as a putative prostate cancer biomarker because levels in
tissue and serum is reduced or lost with cancer development
[2,3,4,12,20,21,22,23] (Figure 1B). We have confirmed these
findings and also that MSMB is largely prostate specific at the
protein level in tissue (Figure 1A and Figure S2). Recent evidence
suggests that once prostate tumours have developed rs10993994
has little effect on disease progression indicating that any increase
in risk affects the benign gland and initial tumour development
[17]. This is consistent with the loss of MSMB that we have noted
in PIN, which suggests that reduced or lost MSMB expression in
benign prostate is required for malignant transformation. The link
between the MSMB risk allele and expression in tissue was highly
significant (p,0.0001) (Figure 2B). Pronounced heterogeneity was
also noted in tissue with moderate to low expression most
commonly linked to the TT allele (Figure 2A).
Several groups have examined MSMB levels in serum
demonstrating prognostic value after radical prostatectomy
[3,32]. Consistent with the loss of MSMB in tumourigenic glands
(Figure 1B) we have demonstrated a highly significant loss of
MSMB in urine from patients with both low and high Gleason
grade prostate cancer was compared to those with no known
prostate disease (Figure 3A). These results compared favourably
with urinary PSA which has previously been reported to have
potential clinical utility in patients with a serum PSA of 4–10 ng/
ml [28]. Urinary MSMB was not as accurate as serum PSA, the
current gold standard test for diagnosing prostate cancer (AUC of
0.97 for serum PSA and 0.77 for urinary MSMB. However, our
cohorts does not represent the false positive and negatives seen
when PSA is used for population screening suggesting a less biased
cohort should be tested establish the true benefit of urinary MSMB
for prostate cancer screening. Although it is perhaps surprising
that such changes are so easily detectable given the potentially
small number of tumourigenic glands within an otherwise benign
prostate. However, we have shown almost complete prostate
specificity for MSMB protein suggesting it is unlikely that
significant levels of MSMB arise from any other tissue. It is likely
that a proportion of men in our normal/benign study (median age
of 53 years) will have some degree of benign prostatic hyperplasia
(BPH) but we noted no significant increase in urinary MSMB with
increasing age suggesting that increased prostate volume has little
effect on urinary MSMB (Figure S4).
Urinary differences in MSMB with the risk allele were
significant but not sufficiently discriminatory our relatively small
cohort. Changes were independent of other established genetic risk
factors such as BRCA1 and BRCA2 mutation (Figure S4). Increased
assay sensitivity and testing a representative population-based
MSMB and rs10993994 Correlate
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cohort compared to PSA are more likely to demonstrate any true
clinical significance in using urinary MSMB to estimate risk and
diagnose prostate cancer. Urine is a highly acceptable biological
measure for patients and our findings indicate that MSMB is a
potential target for further investigation as a urinary biomarker for
prostate cancer screening and diagnosis, without the need for a
digital rectal exam. Unlike PSA, previous reports have suggested
that MSMB levels are unaffected by hormone ablation therapy
frequently used in prostate cancer treatment and we need to
determine if MSMB might be useful in monitoring disease burden
in patients undergoing various forms of treatment [2,3,4]. MSMB
may also prove useful in detecting those patients with raised PSA
but a negative biopsy who would benefit from further investiga-
tion.
Quantitative RT-PCR studies of cell lines has previously
demonstrated a link between the rs109939994 T allele and
lowered MSMB mRNA, most likely due to altered transcription
factor binding [19]. The demonstration of a similar association
with urinary MSMB and MSMB staining in benign prostate tissue
reinforces the causal association between MSMB expression and
prostate cancer. Within the prostate MSMB is believed to regulate
apoptosis via cell surface receptors, MAP kinase and AKT [24,25].
We hypothesise that reduced MSMB expression in men with the
high risk allele may reduce prostate cell apoptosis and ultimately
promote less controlled prostate growth. The loss of such a major
regulatory pathway could promote tumourigenesis and provide an
explanation for an increased risk of developing prostate cancer
while having little effect on outcome once cancer has developed
[17].
Our findings raise the possibility that urinary MSMB related to
genotype may be a useful biomarker for screening for prostate
cancer risk and development. This needs to be studied further to
target those men at increased risk for increased surveillance and
early intervention and identify those men with prostate cancer.
Supporting Information
Figure S1 (A) In total 168 tumour patients were studied but not
every patient had tissue, DNA and urine available. From the
cohort 168 had tissue which included benign which was used in
Figure 1. 145 patients had tissue and DNA and were included in
Figure 2. 89 patients also had a urine sample and could be used for
the ELISA shown in Figure 3. (B) Details of the benign and
tumour cohorts used in the study.
Found at: doi:10.1371/journal.pone.0013363.s001 (0.73 MB EPS)
Figure S2 MSMB is prostate specific in normal and tumour
tissues. A multi-normal tissue TMA was stained for MSMB using
immunohostochemistry and a Bondmax autostainer. The array
contained multiple cores from the following tissues; skin, breast,
thyroid gland, oesophagus, kidney, bladder, lung, colon, liver,
ovary, uterus and stomach. Representative images from testes
(seminoma tumour), breast and prostate are shown. MSMB
staining is brown, nuclei are blue.
Found at: doi:10.1371/journal.pone.0013363.s002 (7.19 MB EPS)
Figure S3 The correlation between genotype and age/PSA at
diagnosis and immunohistochemical staining and age/PSA at
diagnosis. n = the number of individuals examined in each group.
p-values were calculated using a 1-way ANOVA with a Kruskal-
Wallis correction.
Found at: doi:10.1371/journal.pone.0013363.s003 (1.21 MB EPS)
Figure S4 (A) Urinary MSMB levels were compared by ELISA
and a 2-tailed t-test. (B) Urinary MSMB values were analysed
according to the age of the individual (years) at the time of sample
collection. (C) PSA measurements for the benign cohort stratified
according to the rs10993994 genotype. (D) Urinary MSMB does
not alter with BRCA mutations. Benign men in Cohort 3 were
genotyped for mutations in BRCA 1 and BRCA 2 which are
known to confer risk of developing prostate cancer. BRCA
genotype was compared with urinary MSMB. Control - no
mutation, BRCA 1 - mutation in BRCA 1, BRCA 2 - mutation in
BRCA 2. For all graphs n= number of samples analysed and p-
values were calculated using a 1-way ANOVA with a Kruskal-
Wallis correction.
Found at: doi:10.1371/journal.pone.0013363.s004 (2.03 MB EPS)
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